Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with Takeda and Novartis
20 sept. 2024 09h00 HE
|
Firefly Neuroscience, Inc.
TORONTO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia
18 sept. 2024 07h00 HE
|
Engrail Therapeutics, Inc.
Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate
10 sept. 2024 16h05 HE
|
Neurona Therapeutics
Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate
Firefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto's FDA-Cleared EEG Device Platform
10 sept. 2024 09h00 HE
|
Firefly Neuroscience, Inc.
TORONTO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
Firefly Neuroscience Appoints Dr. Stella Vnook to its Board of Directors
05 sept. 2024 09h00 HE
|
Firefly Neuroscience, Inc.
TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
Harness Therapeutics Appoints Experienced R&D Executive and Physician-Scientist, Dr Paulo Fontoura, as Non-Executive Director
04 sept. 2024 03h00 HE
|
Harness Therapeutics
Dr Paulo Fontoura brings 20 years’ experience of working in the pharma industry, with the most recent 16 years focusing on translational medicine and clinical development approaches for one of the...
Arvinas to Participate in Upcoming Investor Conferences
29 août 2024 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Firefly Neuroscience CEO Jon Olsen to Present at H.C. Wainwright’s 26th Annual Global Investment Conference September 9-11
26 août 2024 09h00 HE
|
Firefly Neuroscience, Inc.
TORONTO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
Firefly Neuroscience, an AI-Driven Brain Health Company, to Host Shareholder Update Call on September 4th
22 août 2024 09h00 HE
|
Firefly Neuroscience, Inc.
TORONTO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) technology company developing innovative...
Project Mosaic Launches to Bring “Biopsies” to ALS Drug Development
21 août 2024 13h10 HE
|
Project Mosaic
Project Mosaic is proud to announce the launch of a groundbreaking initiative aimed at revolutionizing ALS drug development.